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http://dx.doi.org/10.1016/j.jfma.201The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming
another “SARS-like” threat to the world. It has an extremely high death rate (w50%) as there
is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-
CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises
the hope of alleviating this currently severe situation. In this review, we examined the molec-
ular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to
develop vaccines and antiviral drugs.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
On 20 September 2012, a novel coronavirus isolated from a
60-year-old Saudi man with acute pneumonia and acute
renal failure was reported.1 In May 2013, the WHO adopted
the virus name Middle East respiratory syndrome (MERS)have no conflicts of interest
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3.11.006coronavirus (MERS-CoV), which was defined by the Coro-
navirus Study Group of the International Committee on
Taxonomy of Viruses.2 As of 7 September 2013, the WHO has
been notified of 114 laboratory-confirmed cases in the
Middle East [Jordan, Saudi Arabia (KSA), the United Arab
Emirates (UAE), and Qatar], Europe [France, Germany,
United Kingdom (UK) and Italy], and North Africa (Tunisia),
with 54 deaths.3
The world is facing a new challenge posed by a severe
acute respiratory syndrome (SARS)-like infections in
humans caused by MERS-CoV. Its main clinical manifesta-
tions in patients are pneumonia (or respiratory) failure and
acute renal failure.4 The short-lived but alarming epidemic
SARS-CoV killed nearly 10% of approximately 8000 cases in
the 2002e2003 outbreak.5 The data so far indicate that& Formosan Medical Association. All rights reserved.
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of approximately 50%, implying a big threat to people who
are infected. Clusters of cases including a UK family, and
hospitals in KSA, France and UAE show epidemiological
evidence of human-to-human transmission. Indeed, existing
reports indicate person-to-person transmission occurs,
raising significant concern on the possible emergence of a
global epidemic in the near future.6e8 It is therefore of
utmost importance to pay worldwide attention to find
antiviral drugs and effective vaccines to control its high
death rate and spread.
Coronaviruses are a large family of enveloped, single-
stranded RNA viruses that infect a number of different host
species, including humans. In people, coronaviruses can
cause illnesses ranging in severity from the common cold to
SARS. Coronaviruses can be categorized into four genera,
Alphacoronavirus, Betacoronavirus, Gammacoronavirus,
and Deltacoronavirus.9,10 The genus Betacoronavirus has
four lineages: A, B, C, and D.11 MERS-CoV belongs to lineage
C and is the first lineage C Betacoronavirus known to infect
humans.12
Coronaviruses infect animals and humans. The spike (S)
entry protein binds to a cell surface receptor which pri-
marily determines their tropism. Similar to other corona-
viruses, MERS-CoV utilizes its large surface S protein to
interact with and enter the target cell.13,14 Raj et al13 have
identified that dipeptidyl peptidase 4 (DPP4; also known as
CD26) is its functional receptor. MERS-CoV binds to DPP4 via
the S protein and releases the RNA genome into the target
cell.2 The MERS-CoV S protein is a type-I membrane glyco-
protein and contains S1 and S2 subunits.15 The S1 domain
determines cellular tropism and interacts with the target
cell, while the S2 domain mediates membrane fusion.13,16
According to recent studies, the MERS-CoV receptor bind-
ing domain (RBD) is mapped to the S1 region.17,18 MERS-CoV
RBD binds to the receptor and induces significant neutral-
izing antibody responses, indicating that it can be used as a
candidate target for the development of vaccines and
antiviral drugs.19 Herein, we review recent studies on
MERS-CoV to make suggestions on antiviral vaccine and drug
development.Structure of MERS-CoV RBD
Lu et al15 and other research teams have identified the
crystal structure of MERS-CoV RBD after the discovery of its
receptor.17,20 Structural topology considers a sequence of
secondary structure elements making protein structure
easy to interpret by laying out the 3D structural information
in two dimensions in a manner that makes the structure
clear. Therefore we used Pro-origami to automatically
generate the schematic representation of the MERS-CoV
RBD topology.21 The MERS-CoV RBD has a core and an
external subdomain (Fig. 1A and B). The core subdomain is
a five-stranded antiparallel b sheet (b1, b3, b4, b5, and
b10) decorated by the connecting helices (a1e4 and h1, 2)
and two small b-strands (b2 and b11) (Fig. 1B). Three di-
sulfide bonds stabilize the fold by connecting C383 to C407,
C425 to C478, and C437 to C585 (Fig. 1B). The external
receptor binding subdomain reveals a four-stranded anti-
parallel b sheet with three large strands (b6, b8, and b9)and one small strand (b7) between strands b5 and b10 of
the core domain (Fig. 1B). The b5/6, b7/8 and b9/10
intervening loops touch the core subdomain and anchor the
external to the core (Fig. 1B). There is a long loop con-
taining h3 crosses perpendicular to the b sheet connecting
b7 and b8 strands, and a disulfide bond between C503 and
C526 links the h3 helix to strand b6 (Fig. 1B).
Mechanism of MERS-CoV binding to DPP4
Multifunctional DPP4 plays a major role in glucose meta-
bolism, T-cell activation, chemotaxis modulation, cell
adhesion, and apoptosis.22,23 In humans, it is primarily
expressed on the epithelial cells in the lungs, liver, small
intestine, kidney, and prostate, and on activated leuko-
cytes, while it also occurs in a soluble form in the circula-
tion.23,24 The structure of DPP4, as shown in previous
studies, is composed of an N-terminal eight-bladed b-pro-
peller domain (S39 to D496) and a C-terminal a/b-hydrolase
domain (N497 to P766).25,26 The b-propeller domain con-
tains eight blades, each made up of four antiparallel b-
strands. The receptor-binding subdomain of MERS-CoV RBD
binds to the DPP4 b-propeller, contacting blades four and
five and a small bulged helix in the blade-linker.15,20
Structural analysis and mutational analysis by Lu et al15
and Wang et al20 have identified Y499, L506, W533, and
E513 in the RBD to be critical for receptor binding and viral
entry, and mutations of these significantly abrogate its
interaction with DPP4.
MERS-CoV RBD-based vaccine design
One reason for the exceptionally high crude mortality rate
of nearly 50% in MERS-CoV infection is the lack of vaccines.
Therefore, it is necessary to develop efficient and safe
vaccines to control MERS quickly. MERS-CoV infects a wide
variety of host species whereas coronaviruses generally
tend to have a narrow host tropism.1 DPP4 sequence
alignment demonstrates that its orthologs are highly
conserved for MERS-CoV acquiring cross-species trans-
missibility by binding to an evolutionarily conserved re-
ceptor.27 Minor mutations within the RBD domain can
disturb the lock-and-key interaction of the RBD-receptor
binding interface and then places a barrier for cross-
species transmission.
The roles of MERS-CoV RBD in receptor binding indicate
that vaccines based on it could induce antibodies to block
virus binding or infection. Among structural proteins of
MERS-CoV, S protein is known to be the main antigenic
component to induce significant neutralizing antibody re-
sponses up to now.19 Du et al19 found that MERS-CoV RBD
binds to the receptor and induces significant neutralizing
antibody responses. Mou et al18 revealed that MERS-CoV
RBD can efficiently elicit neutralizing antibodies. Besides,
previous studies have shown that the related RBD of SARS-
CoV strongly reacts with antisera from patients with SARS
and the depletion of the RBD-specific antibodies results in
significant elimination of the neutralizing activity.28 Lu
et al2 also proposed that SARS vaccines based on SARS-CoV
RBD are more effective and safer than vaccine candidates
based on the inactivated virus, DNA or viral vectors. In
Figure 1 Structure of MERS-CoV RBD (PDB: 4KQZ). (A) A cartoon illustration of the structure of MERS-CoV RBD. The core sub-
domain is shown in yellow and the external subdomain is shown in green. (B) A schematic representation of MERS-CoV RBD topology.
The N and C termini are labeled. Arrows denote b strands and cylinders denote a helices. Purple sticks represent the disulfide
bonds. Connected residues are also labeled.
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vaccine against MERS-CoV following an experimental path
the same as that of the RBD-based SARS vaccine. Therefore,
we strongly believe that MERS-CoV RBD is an important
candidate target for developing MERS vaccines.MERS-CoV RBD-based drug design
Up to now, no effective antiviral drugs against MERS-CoV
have been discovered, which is another factor contrib-
uting to the high death rate. Fortunately, the structure of
MERS-CoV RBD and the mechanism of MERS-CoV binding to
its cell surface receptor have been revealed. They are
very important information for computer-aided drug
design, which is a promising approach to finding novel
drugs for MERS. With that, virtual screening (VS) andstructure-based drug design (SBDD) can be implemented
to find candidate drugs from molecular databases such as
ZINC, PubChem, DrugBank, and so on.30e32 The structural
comparison between MERS-CoV and SARS-CoV RBDs shows
that although their core subdomains are homologous and
similar in structure, their receptor binding subdomains
are clearly different. Thus, the core subdomain is an
effective candidate target not only for anti-MERS-CoV
therapeutics, but also for anti-Betacoronavirus treat-
ments.15
Generally, the identification of pockets and cavities of
the protein structure is essential for VS and SBDD, while
the binding pocket of MERS-CoV RBD remains unknown. In
practice, the current situation is not so bad. Lu et al15
found that although the engagement of the receptor
does not induce significant conformational changes in
receptor binding motifs, the h2-a4 loop in the RBD core
Figure 2 Ligands binding pocket of MERS-CoV RBD (PDB: 4KQZ). (A) A structural alignment between the free and the receptor-
bounded MERS-CoV RBD. Significant structural variance is observed for the h2-a4 loop in the core subdomain, which is marked with
a black arrow. Yellow: free RBD, the core subdomain; green: free RBD, the external subdomain; blue: the bounded RBD. (B) Surface
representation of MERS-CoV RBD. The orange spheres represent the h2-a4 loop. The candidate binding pocket predicted by
PocketPicker is represented by darker spheres.
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between the free and the bounded conditions (Fig. 2A).
That is to say the RBDeDPP4 interaction is largely
dependent on the conformational variant of the loop.
Therefore, utilizing ligands binding to that region, we can
interfere with the essential conformational change,
consequently preventing MERS-CoV infection. With the
help of PocketPicker, a ligand pocket detection tool, we
found computationally that the correct binding pocket of
MERS-CoV RBD with a buried and a solvent exposed part is
close to the loop (Fig. 2B).33 Therefore, the h2-a4 loop
and its peripheral region are important for VS and SBDD to
find novel efficient antiviral drugs.Summary
Generally speaking, MERS-CoV, the first lineage C Betacor-
onavirus known to infect human beings, has attracted
worldwide attention as it causes SARS-like infections in
humans. To date, neither vaccines nor virus-specific drugs
are available, making MERS-CoV a threat to global public
health. Although the limited data cannot confirm human-
to-human transmission, two new cases that have family
contacts with confirmed patients show an increasing prob-
ability.3,34 MERS-CoV utilizes DPP4 as its cell receptor to
enter the target cell. The RBD is located in the S1 domain of
MERS-CoV S protein and its crystal structure has already
The receptor binding domain is a target 147been determined. The structure exhibits the mechanism of
MERS-CoV binding to DPP4. The identified MERS-CoV RBD
may also facilitate the development of vaccines and effi-
cient treatment and ultimately lower the high crude mor-
tality rate and prevent global spread.
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